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A clinical Providencia stuartii isolate SM662 was recovered from a patient hospitalized in the
intensive care unit at the Military hospital, Tunisia. This isolate was resistant to penicillins,
cephalosporins,  aminoglycosides and ﬂuoroquinolones. A marked in vitro synergy between
ceftazidime  or cefotaxime and amoxicillin–clavulanic acid on Mueller-Hinton agar plates
suggested  the presence of an extended-spectrum--lactamase. In addition, an unusual syn-
ergy  was found between cefepime or aztreonam, and cefoxitin or imipenem on a double disk
synergy test suggesting a VEB-type extended-spectrum--lactamase. The characterization
of  -lactamases and associated resistance genes was performed by isoelectric focusing,
polymerase  chain reaction and nucleotide sequencing. Two -lactamases bands with pI val-
ues  of 5.4 and 7.7, which were matched to TEM-1, VEB-1-a and OXA-2-like -lactamases
were  detected. The blaVEB-1-a gene was found to be associated with complex genetic struc-
tures,  including Re elements. These -lactamases were not transferred by electroporation or
conjugation experiments to the transconjugants and electroporants. Hybridization methods
showed that the extended-spectrum--lactamase encoding gene may  have a chromosomal
localization.  The isolate SM662 produced the quinolone resistance determinants qnrA6 and
aac(6′)-Ib-cr which were successfully transferred. The detection of an associated chromoso-mal  quinolone resistance revealed the presence of a gyrA mutation at codon 83 (Ser83Ile).
This  is the ﬁrst report of the linkage VEB-1-a/OXA-2-like in P. stuartii associated with the
description  of qnrA6 and aac(6′)-Ib-cr genes in this isolate.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDrovidencia stuartii is a frequent cause of urinary tract infec-
1ions  in hospitalized patients. It plays an important role
s  a nosocomial pathogen in the dissemination of plasmid-
ediated resistance.2 P. stuartii is naturally resistant to
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a chromosomally expressed Ambler class C cephalosporinases
(AmpC).1 However, acquisition of ESBL has been reported.1,2
blaVEB-1 gene was  identiﬁed in P. stuartii for the ﬁrst time in
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Table 1 – MICs (g/mL) of various antimicrobial agents obtained for the clinical isolate P. stuartii SM662, its
transconjugants and electroporants and the E. coli HB101 and E. coli DH10B recipients strains.
P. stuartii SM662 HB101 × SM662 E. coli HB101 DH10B/pSM662 E. coli DH10B
Amoxicillin >512 4 8 4 2
Ticarcillin >512 4 8 8 2
Oxacillin 512 <4 <2 2 2
Cefoxitin 64 8 2 4 4
Cefotaxime >512 <4 <2 2 4
Ceftriaxone 512 <4 <2 2 1
Ceftazidime >512 <4 <2 2 1
Aztreonam 512 4 <2 <4 1
Nalidixic acid >512 >512 2 >512 2
Chloramphenicol 256 8 <2 8 2
Tetracycline 512 8 <2 8 <1
Ciproﬂoxacin 64 4 2 8 1
Oﬂoxacin 128 64 2 32 1
Streptomycin 64 256 512 128 1
Tobramycin 128 256 <0.25 128 2
Gentamicin 1 0.5 <0.25 0.5 <0.25
Piperacillin 1 0.5 <0.25 0.5 <0.25
Ertapenem 0.25 <0.25 
Imipenem 2 <2 
Alger.1 VEB-1 -lactamase confers high-level resistance to a
broad  spectrum of cephalosporins; however this activity is
inhibited  not only by clavulanate, but also by cefoxitin and
imipenem.3 Until now, the blaOXA-2 gene has not been detected
in  Providencia genus as to the best of our knowledge, but in
Tunisia  it was  described in clinical strains of Pseudomonas
aeuroginosa.4 A decreased quinolone susceptibility associated
with  qnrA6 and aac(6′)-Ib-cr determinants was  also reported
in  Tunisia in clinical strains of P. stuartii.5 In the current study,
we  report for the ﬁrst time the co-production of chromoso-
mal  blaVEB-1-a and blaOXA-2-like genes in a multidrug resistant
P. stuartii clinical strain isolated at the Military hospital in
Tunisia  and their association with plasmid-mediated qnrA6
and  aac(6′)-Ib-cr determinants.
On  July 2008, a 46-year-old man  was  transferred from a
Tunisian  Regional Hospital and he was  hospitalized in the
intensive  care unit at the Military hospital in Tunis, Tunisia
for  a severe cranial traumatism. Three months thereafter, the
patient  notably diabetic and epileptic was  febrile at any time
and  subsequently developed a chronic infection. According
to  the patient’s medical records, such an infection turned
out  to be urinary tract infection that was  diagnosed follow-
ing  the appearance of an infectious syndrome; it was  treated
with  ceftazidime and oﬂoxacin. At the end of October 2008,
P.  stuartii SM662 isolate was  recovered by a tracheal aspirate,
although  seven days prior to the isolation of this strain he had
received  a course of cefotaxime and ciproﬂoxacin. The patient
was  treated with gentamicin and imipenem. Seven days after
starting  antimicrobial therapy the clinical outcome indicated
treatment failure and the ultimately died.
The P. stuartii SM662 strain was  identiﬁed using an AP20E kit
(Biomèrieux,  Marcy-l’Etoile, France). E. coli DH10B (Invitrogen,
Life  Technologies) and streptomycin resistant E. coli HB101
recipient  strains were used respectively for the electropora-
tion  and conjugation experiments. -Lactamases with known
pIs  were  used as standards: TEM-1 (pI 5.4), TEM-2 (pI 5.6), TEM-
3  (pI 6.3) and SHV-1 (pI 7.6).6 Antimicrobial susceptibility was
determined  by the disk diffusion method on Mueller-Hinton<2 <0.25 <0.25
<2 <2 <1
(MH) agar (Bio-Rad, Marnes La Coquette, France) recom-
mended by the Clinical and Laboratory Standards Institute
(CLSI)  guidelines.7 The isolate was  resistant to multiple antibi-
otics,  including chloramphenicol, kanamycin, tobramycin,
sulphonamide, tetracycline, nalidixic acid, ciproﬂoxacin and
oﬂoxacin  whereas it was  susceptible to imipenem, ertapenem,
gentamicin and piperacillin. The double disc synergy test was
positive  showing a marked synergy between ceftazidime or
cefotaxime  and amoxicillin–clavulanic acid on MH agar plates
and  suggested the presence of a class A ESBL.8 In addition,
an  unusual synergy was found between cefepime or aztre-
onam,  and cefoxitin or imipenem on a double disk synergy
test  suggesting a VEB-type ESBL production according to Naas
et  al.3 The minimum inhibitory concentrations (MICs) (Table 1)
were  determined by the broth microdilution method and inter-
preted  according to the CLSI criteria.6 The strain was  found
intermediately resistant to imipenem according to the novel
CLSI  breakpoints (M100-S23) and the difference on the car-
bapenem’s  activity (imipenem and ertapenem) is due to the
lower  activity of imipenem against Providencia spp., Proteus
spp.  and Morganella morganii.
Whole-cell  DNA from P. stuartii SM662 was  used as a
template for PCR assays. Presence of blaTEM-1, blaVEB-1-a and
blaOXA-2-like genes was  assessed by PCR and sequencing as
previously described.6,9,10 No amplicons were  obtained with
blaSHV and blaCTX-M genes.6,11 Furthermore, multiplex PCR
ampliﬁcations using primers speciﬁc for plasmid-mediated
AmpC -lactamases (CBLs)12 were negative.
VEBcas-F  and VEBcas-B (Eurogentec, Belgium) located at
each  end of the blaVEB-1 cassette were  used to amplify the
entire  blaVEB-1 gene.3 Conditions PCR ampliﬁcation experi-
ments were  performed using primers located in the blaVEB-1a
gene and in the class 1 integron variable region (5′CS–3′CS)
(Eurogentec, Belgium) as described previously.13 Ampliﬁca-
′ ′tion  of the class 1 integron variable region (5 CS–3 CS) was
positive  in SM662 showing size of about 1200 bp. Sequence
analysis showed two genes cassettes arrays: aadB + dfrA1.
A  combination of 5′-CS or 3′-CS primers and VEBINV1 or
b r a z j i n f e c t d i s . 2 0 1 
Fig. 1 – Hybridization patterns with the VEB-1 and OXA-2
probes  after HindIII and SmaI  digestion of genomic DNA.
Lanes  1 and 2, SmaI  fragments with VEB-1 and OXA-2
probes respectively; Lanes 3 and 4, HindIII fragments with
VEB-1  and OXA-2 probes respectively; M,  10-Kb DNA
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EBINV2 (Eurogentec, Belgium), respectively, both primers
eading  outwards from blaVEB-1, was  also used for the determi-
ation of the genetic content of class 1 integron.13 However,
o  PCR fragments were  obtained suggesting that the blaVEB-1a
ene cannot be part of a class 1 integron. This hypothesis
id not guarantee that this gene was  not inserted into a
lass  1 integron, since VEB-1 is usually described as part of
 gene cassette itself located in a class 1 integron.3 A further
CR  performed using primers pair Re1F (repeat element) and
EBcas-B,14 revealed the presence of a PCR fragment of about
.2  Kb and suggested that the blaVEB-1a gene was  associated
o two Re1 repeated elements in the direct orientation. A
revious  report identiﬁed the presence of Re1 repeat elements
equences surrounding the blaVEB-1-a gene in P. aeruginosa 10.2
linical  isolate from India [14].
Analytical isoelectric focusing of crude -lactamase extract
f  P. stuartii SM66215 demonstrated two bands of -lactamases
ctivities with pIs of 5.4 and 7.7. TEM-1 and VEB-1 have both 5.4
hile OXA-2 has the pI 7.7. These -lactamases have been not
ransferred  suggesting that were  not mediated by a conjuga-
ive  or transferable plasmid. The single plasmid transferred
p-SM662) using a plasmid extraction kit GFX Micro Plasmid
rep  (Amersham Biosciences, UK), conferred resistance only to
alidixic acid, oﬂoxacin and tobramycin (Table 1). Hybridiza-
ion  methods after digestion restriction with SmaI and HindIII
Biorad®, Laboratories, France)16 showed that blaVEB-1a and
laOXA-2 like genes may  have a chromosomal localization
Fig. 1). Several studies reported that blaVEB-1-a like genes are
ostly  plasmid located in Enterobacteriaceae, whereas they
re  chromosomally located in P. aeruginosa and Acinetobacter4;1 8(2):211–214  213
baumannii.1 Nonetheless, in our study we  identiﬁed a chro-
mosomal VEB-1-a type ESBL. This ﬁnding is described for the
ﬁrst  time in Tunisia and suggests that blaVEB-1-a can spread
among clinically relevant species. Here, we  describe a mul-
tidrug  resistant P. stuartii SM662 co-produced TEM-1 and the
narrow-spectrum -lactamase OXA-2-like, together with the
ESBL  VEB-1-a. Previous ﬁnding reported the simultaneous
presence of blaVEB-1 and blaoxa-10 genes in a clinical strain of
P.  stuartii V1 isolated from Nigeria17 but our study presents
the  ﬁrst report of the linkage VEB-1-a/OXA-2-like in P. stuartii
SM662  clinical isolate, to the best of our knowledge. Blaoxa-2-like
has been detected in P. aeruginosa isolates from Tunisia;4 this
ﬁnding  indicated that OXA genes can spread progressively
between species.
Interestingly, a marked association was found between
ESBL  production and multidrug resistance. To investigate the
coresistance,  PCR detection and sequencing of the qnrA, qnrB
and  qnrS genes18 and the aminoglycoside/ﬂuoroquinolone-
modifying  enzyme-encoding aac(6′)-Ib-cr gene19 identiﬁed
the  qnrA6 determinant and the variant aac(6′)-Ib-cr on the
same  plasmid. The transconjugants and the electroporants
expressed non-susceptibility to oﬂoxacin, streptomycin and
tobramycin  (Table 1). In our study, aac(6′)-Ib-cr, which encodes
an  aminoglycoside acetyltransferase, was  found associated
with  VEB-1 and OXA-2 -lactamases for the ﬁrst time in clini-
cal  strain of P. stuartii in Tunisia. PCR detection and sequencing
of  an additional chromosomal quinolone resistance determi-
nants  regions (QRDRs)20 did not reveal the presence of gyrB,
parC  and parE, but we  detect a gyrA mutation at codon 83
(Ser-Ile).  This observation may  explain the higher level of resis-
tance  to nalidixic acid in our isolate.
In conclusion, our study indicated for the ﬁrst time in
Tunisia  the dissemination of VEB-1 -lactamase associated
with plasmid-mediated qnrA6 and aac(6′)-Ib-cr-like determi-
nants  in a multidrug resistant P. stuartii clinical isolate. The
presence  of Re sequences surrounding the blaVEB-1-a gene is
worrying since their origin and their function in the mobiliza-
tion  of blaVEB-1-a remain unknown and pose a challenge for the
treatment of hospital infections due to Gram-negative bacte-
ria.  Therefore, the incidence of ESBL-producing bacteria needs
a  continuous monitoring of such multidrug resistant strains
and  warrants further study of their epidemiologic evolution.
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